JP2013520488A - ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法 - Google Patents

ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法 Download PDF

Info

Publication number
JP2013520488A
JP2013520488A JP2012554446A JP2012554446A JP2013520488A JP 2013520488 A JP2013520488 A JP 2013520488A JP 2012554446 A JP2012554446 A JP 2012554446A JP 2012554446 A JP2012554446 A JP 2012554446A JP 2013520488 A JP2013520488 A JP 2013520488A
Authority
JP
Japan
Prior art keywords
perphenazine
crystalline form
aminobutyrate
trimesylate
aminobutyrate trimesylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012554446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520488A5 (enExample
Inventor
アブラハム ヌデルマン，
アダ レファエリ，
イリット ギル−アド，
アブラハム ウェイズマン，
マザル シャウル，
エフラット ハルブフィンガー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of JP2013520488A publication Critical patent/JP2013520488A/ja
Publication of JP2013520488A5 publication Critical patent/JP2013520488A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012554446A 2010-02-24 2011-02-24 ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法 Pending JP2013520488A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30748110P 2010-02-24 2010-02-24
US30748210P 2010-02-24 2010-02-24
US61/307,481 2010-02-24
US61/307,482 2010-02-24
PCT/IB2011/000915 WO2011104637A2 (en) 2010-02-24 2011-02-24 Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same

Publications (2)

Publication Number Publication Date
JP2013520488A true JP2013520488A (ja) 2013-06-06
JP2013520488A5 JP2013520488A5 (enExample) 2014-01-30

Family

ID=44507308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012554446A Pending JP2013520488A (ja) 2010-02-24 2011-02-24 ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法

Country Status (9)

Country Link
US (2) US8377929B2 (enExample)
EP (1) EP2539857A4 (enExample)
JP (1) JP2013520488A (enExample)
CN (1) CN102858345A (enExample)
AU (1) AU2011219529A1 (enExample)
CA (1) CA2789654A1 (enExample)
IL (1) IL221461A0 (enExample)
MX (1) MX2012009821A (enExample)
WO (1) WO2011104637A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
CN101511388B (zh) * 2006-07-17 2012-10-24 特拉维夫大学拉莫特有限公司 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
CA2782514A1 (en) * 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
EP2539857A4 (en) 2010-02-24 2013-07-24 Univ Ramot CRYSTALLINE FORMS OF TRI MESYLATE SALT OF PERPHENAZINE GABA AND METHOD OF MANUFACTURING THEREOF
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545777A (ja) * 2005-06-07 2008-12-18 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1460713A (en) 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5780590A (en) 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
JP2001519754A (ja) 1995-07-13 2001-10-23 アノーメッド・インコーポレイテッド ２−［２−（ジメチルアミノ）エチル］−８，８−ジプロピル−２−アザスピロ［４．５］デカンジマレイン酸塩
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US6130221A (en) 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
BR0015974A (pt) 1999-12-01 2002-07-23 Ucb Sa Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
JP2005097120A (ja) 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd ４−ヒドロキシピペリジン誘導体の非潮解性塩
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
CN100558365C (zh) 2001-09-27 2009-11-11 特拉维夫大学拉莫特有限公司 共轭的精神抑制药及其用途
US7005138B2 (en) 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
CN101247837B (zh) * 2005-06-07 2013-03-20 特拉维夫大学拉莫特有限公司 新的轭合精神活性药物的盐及其制备方法
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
EP2539857A4 (en) 2010-02-24 2013-07-24 Univ Ramot CRYSTALLINE FORMS OF TRI MESYLATE SALT OF PERPHENAZINE GABA AND METHOD OF MANUFACTURING THEREOF
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545777A (ja) * 2005-06-07 2008-12-18 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABRAHAM NUDELMAN ET AL: "A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished", J. MED. CHEM, vol. 51, JPN6014042815, 2008, pages 2858 - 2862, ISSN: 0002914741 *

Also Published As

Publication number Publication date
US8377929B2 (en) 2013-02-19
WO2011104637A3 (en) 2012-02-23
US20130150352A1 (en) 2013-06-13
AU2011219529A1 (en) 2012-08-30
CN102858345A (zh) 2013-01-02
WO2011104637A9 (en) 2012-01-05
EP2539857A2 (en) 2013-01-02
WO2011104637A2 (en) 2011-09-01
EP2539857A4 (en) 2013-07-24
CA2789654A1 (en) 2011-09-01
MX2012009821A (es) 2012-10-09
US20110312948A1 (en) 2011-12-22
IL221461A0 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
JP2013520488A (ja) ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法
CN113365616A (zh) 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮
US8916610B2 (en) Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
US9694004B2 (en) Crystal form
US8729130B2 (en) Methods of using novel solid forms of tacedinaline
WO2012003413A1 (en) Novel solid forms of tacedinaline
HK40061049A (en) 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
NZ621315B2 (en) Novel crystal form of rilapladib
HK1198534B (en) Novel crystal form

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150428